Prolia vs Bisphosphonates: Which Osteoporosis Treatment Is Right for You?

How Each Drug Stops Bone Loss

Bisphosphonates and denosumab both reduce osteoclast activity, but they reach that endpoint by entirely different paths. Bisphosphonates bind permanently to hydroxyapatite in bone mineral and are ingested by osteoclasts, where they inhibit the mevalonate pathway enzyme farnesyl pyrophosphate synthase, triggering osteoclast apoptosis. Denosumab (Prolia) is a fully human monoclonal antibody that binds RANK-L, the cytokine signal that recruits and activates osteoclasts. Block RANK-L and you block osteoclast formation at its source.

That mechanistic difference has direct clinical consequences. Because bisphosphonates embed in bone, their antiresorptive effect persists for months to years after the last dose. Zoledronic acid, for example, retains measurable skeletal effect for 1 to 2 years post-infusion based on data from the HORIZON-PFT extension. [1] Denosumab produces no such residual effect. The FDA-approved prescribing information for Prolia explicitly states that bone turnover markers return to pretreatment levels within 9 months of a missed injection, and vertebral fracture risk rises sharply. [2]

Oral bisphosphonates approved for osteoporosis in the United States include alendronate (Fosamax, generic), risedronate (Actonel, Atelvia), and ibandronate (Boniva). The intravenous option most commonly used is zoledronic acid (Reclast) 5 mg once yearly. All are FDA-approved and carry class I recommendation status in the American Association of Clinical Endocrinology 2020 osteoporosis clinical practice guideline. [3]

Fracture Efficacy: Head-to-Head Numbers

Both drug classes reduce fracture risk meaningfully, but the trial designs differ enough that direct comparisons require care. In the FREEDOM trial (N=7,868 postmenopausal women, T-score between -2.5 and -4.0), denosumab 60 mg every 6 months reduced new vertebral fractures by 68% relative to placebo over 36 months (7.2% placebo vs 2.3% denosumab, P<0.001). Hip fracture risk fell by 40% and nonvertebral fractures by 20%. [4]

Alendronate's key data comes from the Fracture Intervention Trial. In FIT-1 (N=2,027 women with existing vertebral fractures), alendronate 5 to 10 mg daily reduced new vertebral fractures by 47% over 36 months relative to placebo. [5] For hip fracture, the reduction was 51% in that fracture-enriched cohort. In FIT-2, which enrolled women without a prior fracture, vertebral fracture reduction was 44%, but hip fracture reduction did not reach statistical significance.

Zoledronic acid data from HORIZON-PFT (N=7,765) showed a 70% reduction in morphometric vertebral fractures, a 41% reduction in hip fractures, and a 25% reduction in nonvertebral fractures at 36 months versus placebo. [6] Those numbers place zoledronic acid and Prolia in a similar efficacy tier for vertebral outcomes, both outperforming weekly oral alendronate in absolute terms, though the populations and methodologies were not identical.

A 2021 network meta-analysis published in JAMA Internal Medicine pooled 69 trials and concluded that denosumab and zoledronic acid produced the largest reductions in vertebral and nonvertebral fracture risk among all available agents, with largely overlapping confidence intervals between the two. [7]

BMD Gains Over Time

Bone mineral density is a surrogate, not an endpoint, but it predicts fracture risk and guides treatment decisions in practice. Three years of Prolia in FREEDOM increased lumbar spine BMD by 9.2% and total hip BMD by 6.0% versus placebo. [4] Ten-year extension data (FREEDOM Extended) showed continued gains, reaching 21.7% at the lumbar spine and 9.2% at total hip, which is unusually sustained for any antiresorptive. [8]

Alendronate produced lumbar spine gains of roughly 7 to 8% over 3 years in FIT versus placebo. Zoledronic acid produced gains of approximately 6.7% at the lumbar spine and 5.1% at total hip over 3 years in HORIZON-PFT. [6] Across these trials, denosumab's BMD gains appear modestly larger, which aligns with its more complete suppression of bone resorption as measured by urinary N-telopeptide and serum CTX.

Safety Profiles Compared

Bisphosphonate-Specific Risks

The two risks that generate the most clinical discussion are osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). Both are rare at osteoporosis doses. A 2015 task force report from the American Society for Bone and Mineral Research estimated ONJ incidence at 1 in 10,000 to 1 in 100,000 patient-years with oral bisphosphonates for osteoporosis. [9] AFF incidence rises with duration of use; a Swedish register study found the risk increases substantially after 5 years of continuous therapy, which is the basis for the bisphosphonate "drug holiday" concept.

Oral bisphosphonates carry a GI tolerability burden. Alendronate must be taken fasting with 8 oz of water, and the patient must remain upright for 30 minutes. Esophageal irritation and upper GI symptoms affect a meaningful proportion of users, and poor compliance with the dosing instructions reduces efficacy. Delayed-release risedronate (Atelvia) and monthly ibandronate were developed partly to improve tolerability.

Zoledronic acid avoids GI issues entirely but causes an acute-phase reaction in roughly 32% of first-time users (flu-like symptoms, fever, myalgia lasting 1 to 3 days), typically self-limiting and less common after the second infusion. It is also contraindicated when creatinine clearance falls below 35 mL/min.

Denosumab-Specific Risks

Prolia shares the ONJ and AFF risks at similar rare rates. Its distinct concern is rebound-associated vertebral fractures on discontinuation. A 2019 observational study in Osteoporosis International found that among patients who stopped denosumab without transitioning to a bisphosphonate, the rate of multiple vertebral fractures within 12 months was approximately 7.1%. [10] The risk appears highest in patients with existing vertebral fractures at baseline.

Hypocalcemia is more clinically relevant with denosumab than with oral bisphosphonates, particularly in patients with vitamin D deficiency, renal impairment, or hypoparathyroidism. The Prolia prescribing information requires correcting hypocalcemia before each injection and supplementing all patients with calcium 1 to 000 mg and vitamin D 400 IU daily unless hypercalcemia is present. [2]

Infections including serious skin infections (cellulitis) were reported at a slightly higher rate than placebo in FREEDOM (0.3% vs 0.1% for serious skin infections), consistent with RANK-L's role in immune signaling. Clinicians should review vaccination status before starting therapy.

Dosing and Administration

The administration difference between these agents is clinically significant for adherence. Oral bisphosphonate adherence data is sobering: a 2006 retrospective study of 35,537 patients found that fewer than 50% of patients remained adherent to weekly alendronate at 1 year, and non-adherence directly correlated with fracture outcomes. [11]

Prolia's every-6-month injection schedule removes the daily or weekly patient action. The injection is administered by a healthcare professional in a clinical setting, which also ensures the dose is actually delivered. Zoledronic acid's once-yearly IV infusion offers a similar adherence advantage.

For patients with severe renal impairment (CrCl <35 mL/min), oral bisphosphonates and zoledronic acid are generally avoided. Denosumab has no formal renal dose adjustment, though the risk of hypocalcemia increases as GFR falls, requiring more careful calcium and vitamin D management. This makes Prolia the preferred option for many patients on dialysis, a population where osteoporosis is both common and undertreated.

When to Choose Prolia Over Bisphosphonates

Clinical selection is not simply about which drug is "stronger." The AACE/ACE 2020 guidelines stratify patients into high and very-high fracture risk categories, with the same first-line options in both. [3] Denosumab is specifically preferred in the following scenarios:

Patients who cannot tolerate or adhere to oral bisphosphonate regimens. Patients with CrCl <35 mL/min where zoledronic acid is contraindicated. Patients on glucocorticoids who develop bisphosphonate-refractory bone loss. Patients where maximizing BMD gain is the priority, such as those with T-score at or below -3.5.

Bisphosphonates retain advantages in patients where cost is a primary concern (generic alendronate remains one of the lowest-cost osteoporosis options available), in patients who prefer to self-administer rather than visit a clinic, and in patients where the provider plans a defined treatment duration with eventual drug holiday.

Transitioning Between Agents

Switching from bisphosphonate to Prolia is straightforward. Because bisphosphonates leave residual skeletal effect, no washout is required before starting denosumab. The first Prolia injection can be given at or near the time the next bisphosphonate dose would have been due.

Switching from Prolia to a bisphosphonate, however, requires careful timing. The Endocrine Society and NOF both recommend transitioning to a bisphosphonate within 5 to 6 months of the last Prolia dose to prevent the rebound phenomenon. Zoledronic acid is typically preferred for the transition because a single infusion 6 months after the last Prolia injection provides rapid, high bone mineral binding. A 2022 analysis in the Journal of Bone and Mineral Research found that a single dose of zoledronic acid given 6 months after the last denosumab injection preserved BMD gains and substantially attenuated the rebound rise in bone turnover markers. [12]

Where Anabolic Agents Fit: Forteo, Tymlos, and Evenity

Bisphosphonates and Prolia are antiresorptive. For patients with very high fracture risk (T-score at or below -2.5 with a prior fragility fracture, or a T-score at or below -3.0 regardless of history), anabolic or dual-mechanism agents may be considered first.

Teriparatide (Forteo, Eli Lilly) and abaloparatide (Tymlos, Radius Health) are parathyroid hormone receptor agonists given as daily subcutaneous injections, each limited to 24 months lifetime use by the FDA. In the ACTIVE trial (N=2,463), abaloparatide 80 mcg daily reduced new vertebral fractures by 86% at 18 months versus placebo. [13] Teriparatide 20 mcg daily reduced vertebral fractures by 65% at a median of 19 months in the FPT trial (N=1,637). [14]

Romosozumab (Evenity, Amgen/UCB) is a sclerostin inhibitor with both anabolic and antiresorptive properties, given as two 105 mg subcutaneous injections monthly for 12 months, then followed by antiresorptive therapy. In the FRAME trial (N=7,180), romosozumab reduced new vertebral fractures by 73% at 12 months versus placebo. [15] The ARCH trial compared romosozumab followed by alendronate against alendronate alone and found a 48% reduction in vertebral fractures, making it superior to starting with alendronate from the outset in very-high-risk patients. [16]

Romosozumab carries an FDA boxed warning for increased cardiovascular risk (myocardial infarction and stroke) based on ARCH, where the romosozumab arm had more cardiovascular events than the alendronate arm. It is therefore contraindicated in patients with a history of MI or stroke within the preceding year.

The general sequencing principle endorsed by the Endocrine Society and AACE is: anabolic first (in very-high-risk patients), then antiresorptive. Starting with an anabolic agent and following with denosumab or a bisphosphonate produces greater and more durable BMD gains than beginning with antiresorptive therapy. Starting with an antiresorptive and then switching to an anabolic is less effective than the reverse sequence, a concept supported by the DATA-Switch trial, which showed lower BMD gains when teriparatide followed alendronate compared to alendronate following teriparatide. [17]

Drug Holiday: Bisphosphonates vs Prolia

The bisphosphonate drug holiday is a period of planned discontinuation, typically after 3 to 5 years of therapy in patients whose fracture risk has been reassessed as lower (T-score above -2.5, no prior vertebral fracture). The FDA 2011 safety communication and the ASBMR 2016 task force report support holiday consideration at 5 years for oral bisphosphonates and 3 years for zoledronic acid, with reassessment every 2 to 3 years during the holiday. [9]

No analogous "drug holiday" exists for Prolia. Because Prolia has no residual skeletal effect, any unplanned interruption carries the rebound risk described above. The clinical instruction is unambiguous: every 6-month Prolia dose must be given on schedule, or a bridging antiresorptive must be administered. Clinicians starting patients on Prolia should document a shared decision-making conversation acknowledging this commitment.

Cost, Insurance Coverage, and Access

Generic alendronate 70 mg weekly costs approximately $10 to $30 per month at major pharmacies without insurance. Generic risedronate and zoledronic acid are also available generically. Prolia, by contrast, costs approximately $1,100 to $1,300 per injection (two injections per year) without insurance, placing annual cost near $2,200 to $2,600 before any rebates.

Most commercial insurers cover Prolia under the medical benefit (not pharmacy benefit) when administered in-office, but prior authorization is typically required. Standard criteria across plans include a documented T-score at or below -2.5, or a history of fragility fracture, or documented intolerance or failure of an oral bisphosphonate. Medicare Part B covers Prolia when given in a physician's office or outpatient infusion center. Patients who meet clinical criteria but face cost barriers may be eligible for Amgen's patient support program, SupportPlus.

Monitoring Parameters

For patients on any antiresorptive therapy, the minimum monitoring framework includes:

Baseline DXA at treatment initiation, then repeat at 1 to 2 years to assess treatment response. A rise in BMD of 3% or more at the lumbar spine suggests adequate response. Loss of BMD of more than 5% at any site, or any incident fracture on therapy, should prompt assessment for secondary causes, adherence issues, or therapy change.

Serum calcium, phosphorus, 25-OH vitamin D, and renal function should be checked before starting therapy and periodically thereafter, with more frequent checks for Prolia in patients with CKD stage 3b or worse (eGFR <45 mL/min/1.73m2).

Bone turnover markers (serum CTX or P1NP) are optionally useful to confirm biochemical response and may guide holiday timing for bisphosphonates. A serum CTX above 300 pg/mL 2 years after stopping alendronate suggests the holiday can safely continue; a CTX below that level suggests ongoing skeletal protection.

The National Osteoporosis Foundation recommends that patients at high fracture risk have their FRAX score recalculated every 1 to 2 years during treatment to reassess whether continuing, switching, or stopping therapy is appropriate. [18]